Exicure (XCUR) Debt to Equity (2016 - 2024)

Exicure (XCUR) reported Debt to Equity of $0.62 for Q2 2024, up 1.32% quarter-over-quarter from $0.61 in Q4 2021.

Exicure (XCUR) Debt to Equity (2016 - 2024) Analysis & Trends

Exicure has reported Debt to Equity for 7 years, with the latest figure at $0.62 in Q2 2024.

For the quarter ending Q2 2024, Debt to Equity changed N/A year-over-year to $0.62; the trailing twelve-month figure through Jun 2024 stood at $0.62 (changed N/A YoY), and the FY2021 full-year result was $0.61, up 126.87% from the prior year.
Debt to Equity for Q2 2024 stood at $0.62, up from $0.61 in the prior quarter.
The five-year high for Debt to Equity was $1.2 in Q3 2021, with the low at $0.22 in Q3 2020.
Historically, Debt to Equity has averaged $0.53 across 3 years, with a median of $0.46 in 2021.
The largest YoY upside for Debt to Equity was 434.7% in 2021 against a maximum downside of 126.87% in 2021.
Exicure's Debt to Equity stood at $0.27 in 2020, then soared by 126.87% to $0.61 in 2021, then climbed by 1.32% to $0.62 in 2024.
The last three Debt to Equity figures came in at $0.62 (Q2 2024), $0.61 (Q4 2021), and $1.2 (Q3 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	0.32
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	-
9	Abivax	95.45 Bn	95.45 Bn	-	-
10	Exicure	18.48 Mn	15.88 Mn	-	-

Download Data